Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 5
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean pagani (4,696 results)?
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.
Asumda FZ, Campbell NA, Hassan MA, Fathi R, Vasquez Rico DF, Kiem M, Vang EV, Kim YH, Luo X, O'Brien DR, Buhrow SA, Reid JM, Moore MJ, Ben-Yair VK, Levitt ML, Leiting JL, Abdelrahman AM, Zhu X, Lucien F, Truty MJ, Roberts LR. Asumda FZ, et al. Cancers (Basel). 2024 Mar 5;16(5):1050. doi: 10.3390/cancers16051050. Cancers (Basel). 2024. PMID: 38473407 Free PMC article.
The goal of this project was to investigate the potential antitumor effects of upamostat and opaganib, individually and in combination, on cholangiocarcinoma (CCA) xenografts in nude mice. ...Tumor volumes in the upamostat, opaganib, and upamostat plus opaganib …
The goal of this project was to investigate the potential antitumor effects of upamostat and opaganib, individually and in combinatio …
The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy.
Maines LW, Keller SN, Smith RA, Green CL, Smith CD. Maines LW, et al. Int J Mol Sci. 2024 Feb 15;25(4):2322. doi: 10.3390/ijms25042322. Int J Mol Sci. 2024. PMID: 38396999 Free PMC article.
Opaganib inhibits key enzymes in sphingolipid metabolism, including sphingosine kinase-2 and dihydroceramide desaturase, thereby reducing inflammation and promoting autophagy. ...These data further demonstrate that sphingolipid metabolism is a critical regulator of fibroge …
Opaganib inhibits key enzymes in sphingolipid metabolism, including sphingosine kinase-2 and dihydroceramide desaturase, thereby redu …
Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy.
Maines LW, Keller SN, Smith CD. Maines LW, et al. Int J Mol Sci. 2023 Nov 29;24(23):16901. doi: 10.3390/ijms242316901. Int J Mol Sci. 2023. PMID: 38069222 Free PMC article.
Interestingly, opaganib treatment induced crossover immunity in that opaganib-treated B16 cells suppressed the growth of both untreated B16 and LLC cells and opaganib-treated LLC cells inhibited the growth of both untreated LLC and B16 cells. ...Opaganib …
Interestingly, opaganib treatment induced crossover immunity in that opaganib-treated B16 cells suppressed the growth of both …
Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia.
Sarapura Martinez VJ, Buonincontro B, Cassarino C, Bernatowiez J, Colado A, Cordini G, Custidiano MDR, Mahuad C, Pavlovsky MA, Bezares RF, Favale NO, Vermeulen M, Borge M, Giordano M, Gamberale R. Sarapura Martinez VJ, et al. Front Oncol. 2023 Mar 20;13:1143881. doi: 10.3389/fonc.2023.1143881. eCollection 2023. Front Oncol. 2023. PMID: 37020867 Free PMC article.
To this aim we employed the dual SPHK1/2 inhibitor SKI-II and opaganib, a SPHK2 inhibitor that is being studied in clinical trials. ...
To this aim we employed the dual SPHK1/2 inhibitor SKI-II and opaganib, a SPHK2 inhibitor that is being studied in clinical trials. . …
Nuclear SPHK2/S1P induces oxidative stress and NLRP3 inflammasome activation via promoting p53 acetylation in lipopolysaccharide-induced acute lung injury.
Gong L, Shen Y, Wang S, Wang X, Ji H, Wu X, Hu L, Zhu L. Gong L, et al. Cell Death Discov. 2023 Jan 18;9(1):12. doi: 10.1038/s41420-023-01320-5. Cell Death Discov. 2023. PMID: 36653338 Free PMC article.
In the in vivo experiments, it was also observed that treating with Opaganib (ABC294640), a specific SPHK2 inhibitor, could observably alleviate LPS-induced ALI, evidencing by lowered infiltration of inflammatory cells, increased M2 macrophages polarization and reduced oxi …
In the in vivo experiments, it was also observed that treating with Opaganib (ABC294640), a specific SPHK2 inhibitor, could observabl …
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.
Kang Y, Sundaramoorthy P, Gasparetto C, Feinberg D, Fan S, Long G, Sellars E, Garrett A, Tuchman SA, Reeves BN, Li Z, Liu B, Ogretmen B, Maines L, Ben-Yair VK, Smith C, Plasse T. Kang Y, et al. Ann Hematol. 2023 Feb;102(2):369-383. doi: 10.1007/s00277-022-05056-7. Epub 2022 Dec 3. Ann Hematol. 2023. PMID: 36460794 Clinical Trial.
In the current study, we performed a phase I study of opaganib in patients with relapsed/refractory multiple myeloma (RRMM). ...SK2 is an innovative molecular target for antimyeloma therapy. The first-in-class SK2 inhibitor opaganib is generally safe for administrat …
In the current study, we performed a phase I study of opaganib in patients with relapsed/refractory multiple myeloma (RRMM). ...SK2 i …
The Sphingosine Kinase 2 Inhibitor Opaganib Protects Against Acute Kidney Injury in Mice.
Maines LW, Green CL, Keller SN, Fitzpatrick LR, Smith CD. Maines LW, et al. Int J Nephrol Renovasc Dis. 2022 Nov 17;15:323-334. doi: 10.2147/IJNRD.S386396. eCollection 2022. Int J Nephrol Renovasc Dis. 2022. PMID: 36420520 Free PMC article.
Opaganib also markedly decreased these parameters and completely prevented mortality in the severe renal IR model. Additionally, opaganib blunted the elevations of BUN, creatinine and inflammatory cytokines following exposure to LPS. ...
Opaganib also markedly decreased these parameters and completely prevented mortality in the severe renal IR model. Additionally, o …
Opaganib Protects against Radiation Toxicity: Implications for Homeland Security and Antitumor Radiotherapy.
Maines LW, Schrecengost RS, Zhuang Y, Keller SN, Smith RA, Green CL, Smith CD. Maines LW, et al. Int J Mol Sci. 2022 Oct 29;23(21):13191. doi: 10.3390/ijms232113191. Int J Mol Sci. 2022. PMID: 36361977 Free PMC article.
Therefore, opaganib may suppress toxicity from unintended IR exposure and improve patient response to chemoradiation. ...Mice were treated with opaganib and/or IR (plus cisplatin in the case of FaDu tumors). In both tumor models, the optimal suppression of tumor gro …
Therefore, opaganib may suppress toxicity from unintended IR exposure and improve patient response to chemoradiation. ...Mice were tr …
Recent Progress in the Development of Opaganib for the Treatment of Covid-19.
Smith CD, Maines LW, Keller SN, Katz Ben-Yair V, Fathi R, Plasse TF, Levitt ML. Smith CD, et al. Drug Des Devel Ther. 2022 Jul 12;16:2199-2211. doi: 10.2147/DDDT.S367612. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35855741 Free PMC article. Review.
Recent work demonstrates that opaganib also has antiviral activity against several viruses including SARS-CoV-2. ...Furthermore, acceleration of the clearance of the virus was observed in opaganib-treated patients. Understanding the biochemical mechanism for the ant …
Recent work demonstrates that opaganib also has antiviral activity against several viruses including SARS-CoV-2. ...Furthermore, acce …
Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial.
Winthrop KL, Skolnick AW, Rafiq AM, Beegle SH, Suszanski J, Koehne G, Barnett-Griness O, Bibliowicz A, Fathi R, Anderson P, Raday G, Eagle G, Ben-Yair VK, Minkowitz HS, Levitt ML, Gordon MS. Winthrop KL, et al. Open Forum Infect Dis. 2022 May 11;9(7):ofac232. doi: 10.1093/ofid/ofac232. eCollection 2022 Jul. Open Forum Infect Dis. 2022. PMID: 35832268 Free PMC article.
We thus considered that opaganib could be beneficial for moderate to severe coronavirus disease 2019 (COVID-19) pneumonia. ...These findings support further evaluation of opaganib in this population....
We thus considered that opaganib could be beneficial for moderate to severe coronavirus disease 2019 (COVID-19) pneumonia. ...These f …
13 results